Project Grant DP2AI192733
Award Date 8/21/25
Completion Date 7/31/30
Dollars Obligated $470K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $300,616 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Shy Therapeutics, LLC to develop a novel class of small molecule antifungal therapies. The project aims to identify and optimize new chemical compounds with potent activity against drug-resistant fungal strains such as Cryptococcus neoformans and Candida auris. Key objectives include using structure-activity relationship...
- The National Institute of Allergy and Infectious Diseases (NIAID), under the CFDA 93.855 Allergy and Infectious Diseases Research program, awarded a $300,000 Project Grant to Life Pharms Inc. on September 19, 2025. The grant supports the development of a novel antifungal drug, LP10581, to address the growing public health crisis of invasive, drug-resistant fungal infections. The project aims to further research and testing of this novel compound, which has shown promising in vitro and in vivo...
- The National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, has awarded a $300,156 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) program to Intact Genomics Inc., a minority-owned small business. The funding will support research to identify new antifungal compounds with novel mechanisms of action from filamentous fungi. The key objectives are to demonstrate the use of Aspergillus nidulans as a...
- The Project Grant award of $170,000.00 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855) is focused on the "Structure-Based Design of Antifungal Inhibitors Targeting the Glycosylphosphatidylinositol (GPI) Ethanolamine Phosphate Transferase, MCD4". The research aims to develop new antifungal agents with novel mechanisms of action to address emerging fungal pathogens and growing...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $556,375 Project Grant under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855) to the J. Craig Venter Institute, Inc. (JCVI) to identify the genetic pathways that govern thermoadaptation and virulence traits in the fungal pathogen Histoplasma capsulatum. This research aims to understand the mechanisms that allow Histoplasma, a dimorphic fungus, to sense changes in human body temperature and...
- This $616,588 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to understand the molecular function of unstudied genes in the fungal pathogen Cryptococcus neoformans, a leading cause of fungal meningitis. The research team at the University of California, San Francisco constructed and phenotypically profiled a comprehensive gene deletion collection for C. neoformans to elucidate the...
- This Project Grant award of $782,178 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) aims to develop new antifungal agents against sterolglycoside enzymes found in fungal pathogens. The research team at Stony Brook University is using a high-throughput screening approach to identify inhibitors of the sterolglycoside enzymes SGL1 and SGLA, which are essential for the pathogenicity of Cryptococcus neoformans and Aspergillus...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,193,457 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) program to the University of Massachusetts Medical School (UMASS Medical) to produce, validate, and provide relevant fungal antigens to the scientific community. The funding will support the manufacturing of crude antigenic preparations from various fungal pathogens, as well as the recombinant production and testing of 36...
- This federal Project Grant award for $489,500 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports research focused on identifying non-conserved regulatory elements in the cell wall stress response of the fungus Candida albicans and testing non-conserved protein regions to discover novel antifungal drug targets. Key objectives include characterizing a cell wall stress...
- This federal Project Grant award in the amount of $423,236 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The purpose of the grant is to characterize a novel hypoxia cell-cycle checkpoint in the pathogenic yeast Cryptococcus neoformans. The key objectives are to: 1) analyze changes in cell-cycle events as Cryptococcus cells transition from log-phase growth to saturation arrest, 2)...